Next Investors logo grey

US Defense finishes latest research on Immuron’s Travelan®


Published 16-JUL-2018 12:19 P.M.


4 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Immuron Limited (ASX:IMC | NASDAQ:IMRN) announced today its three US Defense Health funded research projects on Travelan have been successfully completed.

The studies, commissioned by the US Department of Defense (DoD), were designed to evaluate Travelan’s ability to neutralise pathogenic bacteria of interest, including Campylobacter, ETEC and Shigella bacterial infections. Travelan was shown to bind and was reactive to all strains of bacteria tested.

Now the company will progress with an evaluation of the therapeutic efficacy of Travelan in pre-clinical Shigellosis studies.

“Travelan has been designed to target selected surface antigens from the most common strains of Enterotoxigenic E. coli (ETEC), bacteria which play a dominant and causative role in Travellers’ diarrhea,” Immuron CEO Dr Jerry Kanellos said.

“The work completed at the US Armed Forces Research Institute of Medical Sciences, US Naval Medical Research Center and the Walter Reed Army Institute of Research has highlighted that in laboratory testing Travelan was effective across all strains and species of enteropathogenic bacteria tested.

“The specificity of antibodies incorporated into Travelan cross-react with multiple Campylobacter, ETEC and Shigella strains. The product is truly cross-reactive indicating a substantially broader spectrum of antimicrobial action than previously reported. This new research offers a pathway to further testing which could lead to a major new preventative modality for the US DoD.”

Of course, it should be noted that Immuron is still a speculative stock and anything can happen. Investors should seek professional financial advice if considering this stock for their portfolio.

The studies so far — completed at US Armed Forces Research Institute of Medical Sciences (AFRIMS), US Naval Medical Research Center (NMRC) and the Walter Reed Army Institute of Research (WRAIR) — have highlighted that in laboratory testing Travelan was effective across all strains and species of enteropathogenic bacteria.

The three completed studies commissioned by the DoD are as follows:

  • AFRIMS Study demonstrated Travelan effectively reacted to 180 clinical isolates tested from personnel infected with Campylobacter, Enterotoxigenic Escherichia coli (ETEC) and Shigella. This first study involving Travelan® was performed at the Department of Enteric Diseases, Armed Forces Research Institute of Medical Sciences (AFRIMS). The findings of this comprehensive study were reported by the company in January 2018.
  • NMRC Study demonstrated Travelan bound to and neutralized key components used by the ETEC bacteria to attach to host cells and cause disease. This study was performed by the Department of Enteric Infections, US Naval Medical Research Center (NMRC) and reported that Travelan was specifically shown to;

- React with the major colonization factor antigens.

- Bind to key fimbrial proteins which are used by the bacteria to attach to host cells and cause disease.

- Inhibit the bacteria binding and causing cell hemagglutination.

- React with the heat labile enterotoxin sub-unit B (LTB) produced by Vibrio spp. (the causative agent of cholera).

  • WRAIR Study demonstrated Travelan bound to similar targets present on ETEC and Shigella bacteria. The Department of Enteric Infections, Bacterial Diseases Branch at the Walter Reed Army Institute of Research, assessed Travelan immune-reactivity with ETEC and Shigella antigens, which demonstrated they were reacting to common bacterial antigens.

The global burden of diarrhoeal diseases like Shigella dwarfs any of the more complex diseases seen in gastroenterology clinics. There are an estimated 1.5 billion episodes of diarrhoea worldwide each year, and these episodes result in the deaths of approximately 2.2 million people — mostly children in developing countries.

Shigella in particular is estimated to cause 80–165 million cases of disease worldwide, resulting in 600,000 deaths annually — and is particularly prevalent in both sub-Saharan Africa and South Asia. For the US DoD, a preventative treatment that protects against enteric diseases, specifically Shigella, is a high priority objective, particularly with its strong presence in south-east Asia.

IMC has proprietary vaccines it uses to immunise cows which target specific bacteria, toxins or spores — so when it comes to calving time, the end result is colostrum that is full of antibodies it needs to make its specific, targeted products.

To follow these successful studies, IMC is now pursuing a research agreement with the CSIRO to develop Shigella specific anti-microbial therapeutics for preclinical evaluation.

The company has also just submitted a grant funding proposal for the development of a therapeutic product against campylobacter and other enteric pathogens, jointly with the campylobacter research team at the NMRC.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.